<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /home/lopez/grobid/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Activation of Basophils Is a New and Sensitive Marker of Biocompatibility in Hemodialysis</title>
			</titleStmt>
			<publicationStmt>
				<publisher>Wiley</publisher>
				<availability status="unknown"><p>Copyright Wiley</p>
				</availability>
				<date type="published" when="2014-04-09">2014-04-09</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zenib</forename><surname>Aljadi</surname></persName>
							<email>zenib.aljadi@ki.se</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Medicine</orgName>
								<orgName type="department" key="dep2">†Unit of Translational Immunology</orgName>
								<orgName type="department" key="dep3">Department of Medicine</orgName>
								<orgName type="department" key="dep4">‡Division of Proteomics and Nanobiotechnology</orgName>
								<orgName type="department" key="dep5">School of Biotechnology</orgName>
								<orgName type="department" key="dep6">§Department of Nephrology</orgName>
								<orgName type="laboratory">Unit of Clinical Immunology and Allergy</orgName>
								<orgName type="institution" key="instit1">Karolinska University Hospital Solna</orgName>
								<orgName type="institution" key="instit2">Karolinska Institute</orgName>
								<orgName type="institution" key="instit3">Karolinska University Hospital Solna</orgName>
								<orgName type="institution" key="instit4">Karolinska Institute</orgName>
								<orgName type="institution" key="instit5">Royal Institute of Technology</orgName>
								<orgName type="institution" key="instit6">Karolinska University Hospital Solna</orgName>
								<orgName type="institution" key="instit7">Karolinska Institute</orgName>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ladan</forename><surname>Mansouri</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Medicine</orgName>
								<orgName type="department" key="dep2">†Unit of Translational Immunology</orgName>
								<orgName type="department" key="dep3">Department of Medicine</orgName>
								<orgName type="department" key="dep4">‡Division of Proteomics and Nanobiotechnology</orgName>
								<orgName type="department" key="dep5">School of Biotechnology</orgName>
								<orgName type="department" key="dep6">§Department of Nephrology</orgName>
								<orgName type="laboratory">Unit of Clinical Immunology and Allergy</orgName>
								<orgName type="institution" key="instit1">Karolinska University Hospital Solna</orgName>
								<orgName type="institution" key="instit2">Karolinska Institute</orgName>
								<orgName type="institution" key="instit3">Karolinska University Hospital Solna</orgName>
								<orgName type="institution" key="instit4">Karolinska Institute</orgName>
								<orgName type="institution" key="instit5">Royal Institute of Technology</orgName>
								<orgName type="institution" key="instit6">Karolinska University Hospital Solna</orgName>
								<orgName type="institution" key="instit7">Karolinska Institute</orgName>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anna</forename><surname>Nopp</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Medicine</orgName>
								<orgName type="department" key="dep2">†Unit of Translational Immunology</orgName>
								<orgName type="department" key="dep3">Department of Medicine</orgName>
								<orgName type="department" key="dep4">‡Division of Proteomics and Nanobiotechnology</orgName>
								<orgName type="department" key="dep5">School of Biotechnology</orgName>
								<orgName type="department" key="dep6">§Department of Nephrology</orgName>
								<orgName type="laboratory">Unit of Clinical Immunology and Allergy</orgName>
								<orgName type="institution" key="instit1">Karolinska University Hospital Solna</orgName>
								<orgName type="institution" key="instit2">Karolinska Institute</orgName>
								<orgName type="institution" key="instit3">Karolinska University Hospital Solna</orgName>
								<orgName type="institution" key="instit4">Karolinska Institute</orgName>
								<orgName type="institution" key="instit5">Royal Institute of Technology</orgName>
								<orgName type="institution" key="instit6">Karolinska University Hospital Solna</orgName>
								<orgName type="institution" key="instit7">Karolinska Institute</orgName>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Josefin</forename><forename type="middle">M</forename><surname>Paulsson</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Medicine</orgName>
								<orgName type="department" key="dep2">†Unit of Translational Immunology</orgName>
								<orgName type="department" key="dep3">Department of Medicine</orgName>
								<orgName type="department" key="dep4">‡Division of Proteomics and Nanobiotechnology</orgName>
								<orgName type="department" key="dep5">School of Biotechnology</orgName>
								<orgName type="department" key="dep6">§Department of Nephrology</orgName>
								<orgName type="laboratory">Unit of Clinical Immunology and Allergy</orgName>
								<orgName type="institution" key="instit1">Karolinska University Hospital Solna</orgName>
								<orgName type="institution" key="instit2">Karolinska Institute</orgName>
								<orgName type="institution" key="instit3">Karolinska University Hospital Solna</orgName>
								<orgName type="institution" key="instit4">Karolinska Institute</orgName>
								<orgName type="institution" key="instit5">Royal Institute of Technology</orgName>
								<orgName type="institution" key="instit6">Karolinska University Hospital Solna</orgName>
								<orgName type="institution" key="instit7">Karolinska Institute</orgName>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ola</forename><surname>Winqvist</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Aman</forename><surname>Russom</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mårten</forename><surname>Ståhl</surname></persName>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Britta</forename><surname>Hylander</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Division of Nephrology</orgName>
								<orgName type="department" key="dep2">Department of Clinical Sciences</orgName>
								<orgName type="institution" key="instit1">Danderyd Hospital</orgName>
								<orgName type="institution" key="instit2">Karolinska Institute</orgName>
								<address>
									<settlement>Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stefan</forename><forename type="middle">H</forename><surname>Jacobson</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Medicine</orgName>
								<orgName type="department" key="dep2">†Unit of Translational Immunology</orgName>
								<orgName type="department" key="dep3">Department of Medicine</orgName>
								<orgName type="department" key="dep4">‡Division of Proteomics and Nanobiotechnology</orgName>
								<orgName type="department" key="dep5">School of Biotechnology</orgName>
								<orgName type="department" key="dep6">§Department of Nephrology</orgName>
								<orgName type="laboratory">Unit of Clinical Immunology and Allergy</orgName>
								<orgName type="institution" key="instit1">Karolinska University Hospital Solna</orgName>
								<orgName type="institution" key="instit2">Karolinska Institute</orgName>
								<orgName type="institution" key="instit3">Karolinska University Hospital Solna</orgName>
								<orgName type="institution" key="instit4">Karolinska Institute</orgName>
								<orgName type="institution" key="instit5">Royal Institute of Technology</orgName>
								<orgName type="institution" key="instit6">Karolinska University Hospital Solna</orgName>
								<orgName type="institution" key="instit7">Karolinska Institute</orgName>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Joachim</forename><surname>Lundahl</surname></persName>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="department">Department of Medicine</orgName>
								<orgName type="laboratory">Unit of Clinical Immunology and Allergy</orgName>
								<orgName type="institution">Karolinska University Hospital Solna</orgName>
								<address>
									<addrLine>Karolinska Insti-tute</addrLine>
									<settlement>Stockholm</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Activation of Basophils Is a New and Sensitive Marker of Biocompatibility in Hemodialysis</title>
					</analytic>
					<monogr>
						<title level="j" type="main">Artificial Organs</title>
						<title level="j" type="abbrev">Artificial Organs</title>
						<idno type="ISSN">0160-564X</idno>
						<imprint>
							<publisher>Wiley</publisher>
							<biblScope unit="volume">38</biblScope>
							<biblScope unit="issue">11</biblScope>
							<biblScope unit="page" from="945" to="953"/>
							<date type="published" when="2014-04-09" />
						</imprint>
					</monogr>
					<idno type="DOI">10.1111/aor.12297</idno>
					<idno type="PMID">24712758</idno>
					<idno type="PMCID">PMC4257079</idno>
					<idno type="ark">ark:/67375/WNG-T901B47Q-V</idno>
					<idno type="istexId">48066CA1045A53E7B77AEF0D151FD4930653D4C6</idno>
					<ptr type="open-access" target="http://europepmc.org/articles/pmc4257079?pdf=render" />
					<note type="submission">Received October 2013; revised December 2013.</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.2-SNAPSHOT" ident="GROBID" when="2020-08-13T22:12+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>Chronic kidney disease-Hemodialysis-Biocompatibility-Basophil activation-Neutrophil activation</keywords>
			</textClass>
			<abstract>
				<p>The hemodialysis procedure involves contact between peripheral blood and the surface of dialyzer membranes, which may lead to alterations in the pathways of innate and adaptive immunity. We aimed to study the effect of blood-membrane interaction on human peripheral basophils and neutrophils in hemodialysis with high-and low-permeability polysulfone dialyzers. The surface expression of CD203c (basophil selection marker) and CD63 (activation marker) after activation by the bacterial peptide formyl-methionyl-leucyl-phenylalanine (fMLP) or anti-Fcε receptor I (FcεRI) antibody and the absolute number of basophils was investigated before and after hemodialysis with each of the dialyzers. Moreover, the expression on neutrophils of CD11b, the CD11b active epitope, and CD88 was analyzed in the same groups of individuals. The expression of CD63 in basophils following activation by fMLP was significantly higher in the patient group compared with that in healthy controls, but no differences were observed after activation by anti-FcεRI. During the hemodialysis procedure, the low-flux membrane induced up-regulation of CD63 expression on basophils, while passage through the high-flux membrane did not significantly alter the responsiveness. In addition, the absolute number of basophils was unchanged after hemodialysis with either of the dialyzers and compared with healthy controls. We found no significant differences in the expression of the neutrophil activation markers (CD11b, the active epitope of CD11b, and CD88) comparing the two different dialyzers before and after dialysis and healthy controls. Together, these findings suggest that alterations in basophil activity may be a useful marker of membrane bioincompatibility in hemodialysis.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>cellulose membranes were used in the early era of hemodialysis but have long since been substituted by membranes based on modified cellulose (cellulose diacetate and hemophan) and subsequently by membranes manufactured from synthetic polymers (polyacrylonitrile [AN69] or polysulfone). The modified and synthetic materials were introduced to improve the biocompatibility of dialyzers. In previous studies, it has been shown that neutrophils from patients dialyzed with polysulfone membranes have higher functionality compared with cells collected from patients treated with unmodified or modified cellulose membranes <ref type="bibr" target="#b4">(5)</ref>. The hemodialysis procedure induces complement activation, as evidenced by the increased production of complement factors. These factors contribute to dialysis-associated microinflammation through the release of interleukins (ILs) by monocytes, which exert chemotactic activity on neutrophils and monocytes <ref type="bibr" target="#b9">(10)</ref>. The intensity of complement generation is closely dependent on the type of dialysis membrane <ref type="bibr" target="#b10">(11)</ref>. In addition, the permeability of the membrane contributes to the overall biocompatibility properties. High-flux dialyzers (with large pore size and higher ultrafiltration coefficients) have better clearance of large molecules, such as β2-microglobulin and toxins with enzymatic and metabolic inhibitory effect, compared with low-flux dialyzers (with smaller pore size and lower ultrafiltration coefficients), but the clinical consequences in terms of morbidity and mortality of long-term use are still debated <ref type="bibr" target="#b11">(12)</ref><ref type="bibr" target="#b12">(13)</ref><ref type="bibr" target="#b13">(14)</ref>.</p><p>Basophils constitute a subtype of granulocytes and represent &lt;1% of total circulating leukocytes <ref type="bibr" target="#b14">(15)</ref>. Involvement of basophils in autoimmune kidney diseases, such as lupus nephritis, has previously been observed. Formation of immune complexes may trigger basophils to secrete IL-4 and initiate T helper type 2 (Th2) differentiation, B-cell proliferation, plasma cell differentiation, and immunoglobulin production, responsible for the ongoing humoral immune response in affected tissues <ref type="bibr" target="#b15">(16,</ref><ref type="bibr" target="#b16">17)</ref>. It has also been proposed that hemodialysis patients display IgE-mediated anaphylactic reactions and that basophils from patients with autoimmune kidney disease up-regulate the cell surface expression of markers such as CD203c and CD63 upon activation <ref type="bibr" target="#b17">(18,</ref><ref type="bibr" target="#b18">19)</ref>. Studies have previously shown that neutrophil activity can be used to reflect the biocompatibility properties of different dialyzers. For example, CD11b expression on neutrophils was increased after hemodialysis with unsubstituted and substituted cellulosic membranes, while it was similar to that in healthy controls after hemodialysis with synthetic polysulfone membranes <ref type="bibr" target="#b6">(7)</ref>.</p><p>Given the potential impact of the dialysis procedure on granulocyte function, we aimed to investigate the differences in activation of basophils (CD63 expression) and neutrophils (expression of CD11b and the active epitope of CD11b) and in CD88 expression in CKD patients undergoing hemodialysis with high-flux or low-flux polysulfone membranes, compared with that observed in healthy controls.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>PATIENTS AND METHODS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Study population</head><p>The hemodialysis patients were recruited from the Department of Nephrology at the Karolinska University Hospital in Stockholm, Sweden. The patients had an estimated glomerular filtration rate (eGFR) of &lt;20 mL/min/1.73 m 2 with a residual GFR of 6-11 mL/min/1.73 m 2 (median 7). Patients were undergoing hemodialysis with high-flux polysulfone dialyzers three times per week for 4-4.5 h per dialysis before the study (n = 10). The dialysis vintage in this group was 4-84 months with median duration of 24 months, and dialysis was done via an arteriovenous fistula (n = 8) or a central dialysis catheter (n = 2). Patients with cancer, an ongoing infection, or chronic inflammatory disease and those taking immunosuppressive drugs were excluded. Healthy controls were recruited among healthy blood donors (n = 10), all sex-and age-matched (±5 years) with the hemodialysis patients. Demographic characteristics of all participants are shown in <ref type="table" target="#tab_0">Table 1</ref>. The patients were treated with diuretics, beta-blockers, angiotensinconverting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, or a combination of these drugs <ref type="table" target="#tab_0">(Table 1)</ref>. Participants filled out a questionnaire regarding their health status, current comorbidities, medication, and vaccination status against hepatitis and influenza virus prior to the study. Written informed consent was obtained from all participants.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Dialysis procedure</head><p>Before the study, the patients were routinely undergoing hemodialysis with a high-flux polysulfone capillary hemodiafilter with an effective surface area of 2.3 m 2 (K0A urea: 1421 mL/min; ultrafiltration coefficient: 76 mL/h/mm Hg; sterilization method: inline steam; FX corDiax 1000, Fresenius AG, Bad Homburg, Germany). In one session of treatment, the dialyzer was shifted to a low-flux polysulfone capillary dialyzer with an effective surface area of 1.8 m 2 (K0A urea: 976 mL/min; ultrafiltration coefficient: 14 mL/h/mm Hg; sterilization method: inline steam; Z. ALJADI ET AL. 946 FX 10, Fresenius AG). The dialyzers were not reused, and interdialytic weight gain was less than 5%, indicating similar ultrafiltration volumes. The purity of the dialysate fluid was tested at recommended intervals according to the European best practice guidelines <ref type="bibr" target="#b19">(20)</ref> and was found to be pure at all occasions.</p><p>Peripheral blood samples were drawn before and after hemodialysis in each session (one session with high flux and one session with low flux).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Determination of CD203c and CD63 expression in basophils</head><p>Initially, samples from eight study subjects were analyzed: four samples from healthy controls and four pre-high-flux hemodialysis samples. Whole blood was drawn into heparin tubes (Vacutainer, Becton Dickinson, Oxford, UK) and then incubated with different concentrations of stimulators (formylmethionyl-leucyl-phenylalanine [fMLP] and anti-Fcε receptor I [FcεRI] antibody) to achieve the optimal concentration for a maximum basophil activation response <ref type="bibr" target="#b20">(21)</ref>. fMLP was diluted in RPMI 1640 medium (Sigma Aldrich, Taufkirchen, Germany) and concentrations of 10 −6 to 5 × 10 −5 M were prepared. Anti-FcεRI antibody (3 μg/mL) (Bühlmann Laboratories, Schönenbuch, Switzerland) was diluted (1:3) in stimulation buffer (Bühlmann Laboratories) and concentrations of 0.11 μg/mL to 3 μg/mL were prepared accordingly. Whole blood (100 μL) was distributed among polystyrene tubes (Falcon, Becton Dickinson, Franklin Lakes, NJ, USA) and incubated with the relevant concentrations of fMLP and anti-FcεRI antibody at 37°C for 25 min to initiate the degranulation of basophils and histamine release. Subsequently the cells were stained with 18 μL of anti-CD203c-PE and CD63-FITC antibodies (Beckman Coulter, Paris, France) and incubated for 25 min at 4°C. Following lysis of red blood cells (RBCs) with 2 mL cold isotonic solution (154 mM NH4Cl, 10 mM KHCO3 supplemented with 0.1 mM EDTA, pH 7.2), samples were centrifuged for 5 min at 300 × g at 4°C; cells were then washed once with phosphate buffered saline (PBS) before being resuspended in 300 μL of cold PBS and subsequently analyzed. The surface expression of CD203c and CD63 on basophils was analyzed by flow cytometry (Navios, Beckman Coulter, Hialeah, FL, USA). Basophils were gated according to their granularity on side scatter and expression of CD203c <ref type="figure" target="#fig_0">(Fig. 1a)</ref>. The percentage of CD63-positive cells within the total basophil population was calculated as shown in <ref type="figure" target="#fig_0">Fig. 1b</ref>. Data were analyzed with Kaluza analysis software (Beckman Coulter).</p><p>After the optimal concentrations of fMLP and anti-FcεRI antibody were found, the same procedure was applied on the rest of the samples after incubation of 100 μL of whole blood with RPMI medium (as negative control), RPMI medium containing fMLP at a concentration of 5 × 10 −5 M, and anti-FcεRI antibody at a concentration of 3 μg/mL in separate tubes.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Estimation of absolute number of basophils</head><p>The absolute number of basophils was estimated in 100 μL of whole blood by using the ImmunoPrep reagent system (Beckman Coulter) according to manufacturer's instructions. Subsequently, 100 μL of pretreated whole blood was mixed with 100 μL flow-count beads (Beckman Coulter) before flow cytometric analysis. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BASOPHIL ACTIVATION IN HEMODIALYSIS 947</head><p>Flow cytometric analysis of surface CD11b, active CD11b, and CD88 expression on neutrophils Whole blood was drawn into EDTA tubes (Vacutainer, Becton Dickinson) before and after the hemodialysis procedure with high-and low-flux dialyzers, respectively. Blood (150 μL) was distributed in polystyrene tubes and mixed with 2 mL cold isotonic solution to lyse the erythrocytes. After 5 min, the tubes were centrifuged for 5 min at 300 × g at 4°C, the supernatant was discarded, and the cells were washed with PBS. The tubes were divided into three groups: the unstimulated cells, the cells stimulated with increased temperature (+37°C), and the cells stimulated with IL-8 (CXCL8) (Research &amp; Diagnostics Systems, Abingdon, UK). RPMI 1640 medium (200 μL) mixed with 10% fetal calf serum was added to all the tubes. IL-8-stimulated cells were stimulated with a final concentration of 100 ng/mL IL-8 <ref type="bibr" target="#b21">(22)</ref>. The unstimulated cells were incubated on ice, while the stimulated cells were incubated at 37°C for 30 min. The tubes were washed with PBS, and cells were resuspended in 100 μL of cold PBS. Antibodies were added to the relevant tubes-anti-CD11b-FITC (Beckman Coulter; 20 μL) and anti-CD11b-PE (activated form, clone CBRM1/5, BioLegend Inc., San Diego, CA, USA; 20 μL), as well as corresponding isotype controls (IgG1). The tubes were incubated for 30 min at 4°C. The cells were washed with PBS, resuspended in 350 μL of cold PBS, and subsequently analyzed. Data acquisition was conducted by flow cytometer, and data were analyzed using the Kaluza analysis software.</p><p>Neutrophils were gated according to their size and granularity on forward and side scatter as shown in <ref type="figure" target="#fig_0">Fig. 1c</ref>. The mean fluorescence intensity (MFI) of CD11b + cells and percentage of active-CD11b + cells were measured within region G, according to the gates set by the respective isotype controls. For detection of CD88 expression, 150 μL of blood was added to polystyrene tubes, RBCs were lysed, and cells were washed with PBS, resuspended in 100 μL of PBS, and incubated with 20 μL anti-CD88 anti-body (Becton Dickinson) for 30 min, then washed once and, after addition of PBS, analyzed with flow cytometry.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p>Scatter plots were prepared using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA), representing the range with whiskers and the median as a middle line. Statistical analysis was done in GraphPad Prism 5. As the study population was not normally distributed, comparison between the groups was performed by the nonparametric Kruskal-Wallis test. Significant differences between groups were analyzed using the post hoc Wilcoxon matched-pairs signed-rank test. A P value of &lt;0.05 was considered significant.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ethics statement</head><p>The study was approved by the local ethical committee at the Karolinska University Hospital, Stockholm, Sweden (2012/1027/32).</p><p>Written informed consent was obtained from all participants.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Laboratory findings</head><p>The laboratory data for the study participants are shown in <ref type="table">Table 2</ref>. There were no significant differences between the groups with regard to total leukocyte and platelet counts. The erythrocyte count was significantly higher in healthy controls compared with patients, but no differences were seen when comparing pre-and postdialysis samples with either of the dialyzers. Serum albumin was significantly lower in hemodialysis patients before the procedure compared with healthy controls.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Absolute number of basophils following dialysis with high-flux and low-flux dialyzers compared with healthy controls</head><p>The absolute number of basophils was calculated by flow cytometry to investigate the effect of dialyzer </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Z. ALJADI ET AL. 948</head><p>membrane on the number of cells. There were no significant differences in the absolute number of basophils following hemodialysis with high-flux or low-flux dialyzers. In addition, the absolute number was similar to that of healthy controls ( <ref type="table" target="#tab_1">Table 3)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Optimization of basophil activation response to different concentrations of fMLP and anti-FcεRI antibody (dose-response curve)</head><p>Basophils were stimulated by various concentrations of fMLP (bacterial peptide) and anti-FcεRI antibody, and the activation response (CD63 expression) to stimulators was analyzed as shown in <ref type="figure" target="#fig_1">Fig. 2</ref>. Basophil activation response to fMLP at various concentrations reached a plateau, and therefore the concentration of 5 × 10 −5 M was chosen as the optimal concentration ( <ref type="figure" target="#fig_1">Fig. 2a</ref>).</p><p>Anti-FcεRI antibodies act by cross-linking the receptors on the surface of basophils and are a stronger stimulator for degranulation. The maximum response of basophils was to anti-FcεRI antibody was observed at the concentration of 3 μg/mL, and the lowest observed stimulation was seen at a concentration of 0.11 μg/mL <ref type="figure" target="#fig_1">(Fig. 2b</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Basophil activation response to fMLP and anti-FcεRI antibody comparing hemodialysis patients with healthy controls</head><p>The expression of CD63 in basophils was analyzed following fMLP and anti-FcεRI antibody stimulation. Samples from patients on hemodialysis, obtained before each session of dialysis with highflux or low-flux dialyzers, were compared with those from healthy controls (n = 10 in each group). The</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>TABLE 2. Laboratory data for blood parameters (n = 14)</head><p>Leukocyte count (×10 9 /L)</p><formula xml:id="formula_0">Erythrocyte count (×10 12 /L) Platelet count (×10 9 /L) Creatinine (μmol/L) Albumin (g/L) CRP (mg/L)</formula><p>Values are given as median and interquartile range (25-75%). a P = 0.0006 compared with healthy controls; b P = 0.04 compared with healthy controls; c P = 0.0005 compared with healthy controls; d P = 0.026 compared with healthy controls; e P = 0.02 compared with post-HFD; f P = 0.00001 compared with healthy controls; g P = 0.04 compared with post-LFD; h P = 0.00001 compared with healthy controls; i P = 0.03 compared with healthy controls; j P = 0.04 compared with healthy controls.</p><p>CRP, C-reactive protein; HFD, high-flux dialysis; LFD, low-flux dialysis. The absolute number of basophils (cells/μL) was calculated in peripheral blood before and after dialysis with high-flux and low-flux membranes. Values are given as median and interquartile range (25-75%).</p><p>HFD, high-flux dialysis; LFD, low-flux dialysis. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BASOPHIL ACTIVATION IN HEMODIALYSIS 949</head><p>CD63 expression in fMLP-activated basophils from patients was significantly higher compared with that in healthy controls <ref type="figure">(Fig. 3a)</ref>. However, basophil activation following stimulation by anti-FcεRI antibody was not significantly different between the groups <ref type="figure">(Fig. 3b</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Difference in basophil activation response following hemodialysis with high-flux and low-flux dialyzer membranes</head><p>The CD63 expression in fMLP-and anti-FcεRI antibody-activated basophils was analyzed before and after hemodialysis with each type of dialyzer membrane.</p><p>Following stimulation with fMLP, we observed no significant differences in CD63 expression comparing predialysis samples with postdialysis samples in any type of dialyzer; however, there was increased cell surface expression of CD63 on basophils after dialysis with the low-flux dialyzer compared with the highflux dialyzer (P = 0.01) <ref type="figure">(Fig. 4a)</ref>.</p><p>The results demonstrated that anti-FcεRI antibody-activated basophils expressed significantly higher levels of CD63 following hemodialysis with the low-flux membrane (compared with before dialysis) (P = 0.002). This finding was in contrast with that of cells subjected to interaction during high-flux hemodialysis. Moreover, basophil activation response to anti-FcεRI antibody in low-flux membrane-treated cells was significantly higher than in high-flux membrane-treated cells (P = 0.002) as shown in <ref type="figure">Fig. 4b</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Flow cytometric analysis of surface expression of CD11b, active CD11b, and CD88 on neutrophils</head><p>No significant differences were observed in terms of CD11b expression (MFI) on neutrophils before stimulation (baseline) when comparing dialysis patients with healthy controls and comparing highflux dialyzer with low-flux dialyzer <ref type="figure">(Fig. 5a)</ref>. In order to evaluate whether the cells had been differently primed, cells were stimulated with IL-8, a major factor regulating the expression of CD11b <ref type="bibr" target="#b21">(22)</ref>. The surface expression of CD11b (MFI) was increased after stimulation with IL-8, but the expression was similar when comparing cells subjected to high flux with those subjected to low flux and cells from healthy controls <ref type="figure">(Fig. 5b)</ref>. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Z. ALJADI ET AL. 950</head><p>There were no significant differences in active CD11b expression (percentage) on neutrophils before stimulation (baseline) comparing hemodialysis patients with healthy controls or comparing the effects of high-flux and low-flux dialyzers <ref type="figure">(Fig. 6a)</ref>. Furthermore, no significant differences were observed in active CD11b expression (percentage) on neutrophils after stimulation with IL-8 comparing dialysis patients with healthy controls and comparing high-flux and low-flux dialyzers <ref type="figure">(Fig. 6b</ref>).</p><p>There were no significant differences in the expression of CD88 on neutrophils after hemodialysis comparing high-flux and low-flux dialyzers (data not shown). The data were similar to those in healthy controls.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p>In the present study, we demonstrate for the first time that blood interaction with dialysis membranes impacts the responsiveness of basophils in patients on maintenance hemodialysis. Moreover, responsiveness of basophils differs according to whether low-or high-flux polysulfone membranes are used. Interestingly, no concomitant changes in neutrophil activation were noticed.</p><p>Our data demonstrate that the basophil response to fMLP was higher in the dialysis patient group compared with healthy individuals. However, anti-FcεRI stimulation response did not differ between the patients and healthy subjects. It is not known whether this difference in fMLP response is a conse-quence of altered expression of fMLP receptors or a consequence of primed intracellular pathways. fMLP binds to receptors expressed on basophils, the formyl peptide receptor (FPR) and formyl peptide receptorlike 1 (FPRL1), which activates intracellular signaling pathways such as the MEK-ERK pathway and leads to chemotaxis and release of mediators such as leukotriene C4 and histamine <ref type="bibr" target="#b22">(23,</ref><ref type="bibr" target="#b23">24)</ref>. However, better understanding of the mechanisms involved in fMLP activation of basophils in dialysis patients will require further investigations.</p><p>We also report a difference in FcεRI-mediated activation when basophils pass through a dialyzer. The basophil response was increased after passage through the low-flux polysulfone dialyzer but unchanged following passage through the high-flux membrane. Cross-linking of Fcε receptors on the basophil surface results in a stronger response than activation by fMLP. It has been shown that patients undergoing hemodialysis may develop anaphylactic or anaphylactoid reactions. The underlying mechanism involved in hemodialysis-associated anaphylactic reactions may be related to activation of basophils through cross-linking of FcεRI on the surface of basophils and rapid release of histamine and heparin and a delayed release of IL-4 <ref type="bibr" target="#b17">(18)</ref>. IL-4 is regarded as a key mediator in the tuning of the T-cell differentiation, favoring a Th2 response <ref type="bibr" target="#b24">(25,</ref><ref type="bibr" target="#b25">26)</ref>. The question we addressed in the present study was whether the differences in pore size and ultrafiltration coefficient </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>BASOPHIL ACTIVATION IN HEMODIALYSIS 951</head><p>in high-and low-flux polysulfone membranes have an impact on cell activation, as the clinical use of highflux dialyzers has been suggested to reduce cardiovascular mortality and improve survival <ref type="bibr" target="#b12">(13,</ref><ref type="bibr" target="#b13">14)</ref>, even though there is an ongoing debate regarding the superiority of high-flux dialyzers over low-flux ones <ref type="bibr" target="#b26">(27)</ref>. As high-flux dialyzers are more efficient in removing immune modulators generated during the dialysis procedure, this is in line with our finding of increased basophil activation after low-flux hemodialysis. Previous studies have demonstrated that the hemodialysis procedure may lead to neutropenia, monocytopenia, and thrombocytopenia <ref type="bibr" target="#b27">(28)</ref><ref type="bibr" target="#b28">(29)</ref><ref type="bibr" target="#b29">(30)</ref>. Therefore, we analyzed the absolute number of basophils and did not detect any significant effects on cell number following passage through the different dialyzers. This implies that the variation in the basophil response was due to functional changes and not a consequence of entrapment of low-responding cells in the dialyzer.</p><p>The state of neutrophil activation has previously been shown to be a sensitive marker of biocompatibility in hemodialysis. For example, during neutrophil adhesion and transendothelial migration, there is a rapid translocation of CD11b (a member of the integrin family) from an intracellular pool to the cell surface, followed by receptor aggregation and conformational change in the active epitope <ref type="bibr" target="#b30">(31)</ref>. It is well established that different dialyzer surfaces impact the function of neutrophils. It has been reported that CD11b expression on neutrophils increases at the beginning of hemodialysis with several types of dialyzers but declines to basal level at the end of the procedure with biocompatible dialyzers such as polysulfone membranes, while it remains high after dialysis with bioincompatible membranes <ref type="bibr" target="#b31">(32,</ref><ref type="bibr" target="#b32">33)</ref>. In the present study, we investigated both the surface expression of CD11b and the expression of the active epitope on neutrophils but found no significant differences in the expression of either marker after one session of hemodialysis between the low-flux membrane and the high-flux polysulfone membrane.</p><p>It has been shown that the hemodialysis procedure activates several hemostatic pathways such as generation of C3a and C5a (anaphylatoxins) <ref type="bibr" target="#b33">(34)</ref>, but it has also been reported that neither C5a levels in plasma nor C5a levels in the dialysate compartment increase after dialysis with high-flux and/or low-flux polysulfone dialyzers <ref type="bibr" target="#b34">(35)</ref>. As the molecular weight of C5a is similar to that of β2-microglobulin, this anaphylatoxin can be cleared by high-flux membranes due to a different kinetic gradient. We therefore investigated the expression of C5a receptor type 1 (CD88) on neutrophils as a cellular marker for complement activation. Following interaction with the ligand C5a, the receptors internalize within minutes to induce responses such as chemotaxis of neutrophils with up-regulation of CD11b, granule enzyme release, superoxide anion production, and platelet-neutrophil microaggregation <ref type="bibr" target="#b35">(36)</ref>. In a previous study, a high-flux dialysis membrane induced a decrease in C5a receptor expression on neutrophils in three out of four patients, but internalized C5aR expression showed a nonsignificant change <ref type="bibr" target="#b36">(37)</ref>. We did not find any significant differences in CD88 expression on neutrophils from patients undergoing high-flux hemodialysis compared with low-flux dialysis, which could be due to the difference in number of study subjects or insensitivity of this molecule for assessment of bioincompatibility.</p><p>The hemodialysis procedure induces secretion of several inflammatory mediators besides anaphylatoxins that can impact basophil function, such as IL-1β and tumor necrosis factor α, from activated monocytes. Of interest is that earlier studies reported a correlation between the cytokine IL-1 and the induction of histamine release from basophils <ref type="bibr" target="#b37">(38)</ref>. Bradykinin generation has been reported to be increased during hemodialysis with polysulfone membranes, which can be explained by the fact that the membrane surface carries negatively charged groups, which may activate the Hageman factor (coagulation factor XII), known to convert prekallikrein to kallikrein, which will generate bradykinin from high-molecular-weight kininogen <ref type="bibr" target="#b38">(39,</ref><ref type="bibr" target="#b39">40)</ref>. The bradykinin can trigger the IgE-independent activation of basophils to induce an anaphylactoid reaction during hemodialysis <ref type="bibr" target="#b17">(18)</ref>. Interestingly, we have also recently shown that the level of eotaxin, a potent chemoattractant to basophils (acting through CCR3 receptors), was increased in patients with CKD <ref type="bibr" target="#b40">(41)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONCLUSION</head><p>This study demonstrates that the responsiveness of basophils to anti-FcεRI stimulation is affected when the cells pass through a dialyzer. These changes differ between high-flux and low-flux polysulfone dialyzers in patients with chronic kidney disease. Moreover, we also report an increased responsiveness to fMLP in patients on hemodialysis compared with healthy controls. Together, these data demonstrate that basophil activation may be a new and more sensitive marker for evaluating biocompatibility properties of dialyzers.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>FIG. 1 .</head><label>1</label><figDesc>Flow-cytometric analysis of CD203c and CD63 expression on basophils and CD11b expression on neutrophils. Basophils were gated according to their granularity on side scatter and expression of CD203c (a). The number of CD63-positive cells within the total basophil population was measured (b). Granulocytes were gated according to their size and granularity on forward and side scatter (c).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>FIG. 2 .</head><label>2</label><figDesc>Basophil activation responses to different concentrations of fMLP and anti-FcεRI antibody (dose-response curve). Scatter plots represent the range with whiskers and the median as the middle line. (a) The level of CD63 expression in basophils following activation by fMLP reached a plateau involving four different concentrations. (b) The maximum expression of CD63 in basophils following activation by anti-FcεRI antibody was observed at a concentration of 3 μg/mL and gradually decreased at lower concentrations of stimulator.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>FIG. 3 .FIG. 4 .</head><label>34</label><figDesc>Basophil activation response to fMLP and anti-FcεRI antibody comparing patients with healthy controls. Scatter plots represent the range with whiskers and the median as the middle line. A P value &lt;0.05 was considered significant. (a) CD63 expression in fMLP-activated basophils was significantly different comparing the samples from patients before dialysis with high-flux dialyzer (HFD) with those of healthy controls. Basophils from patients before dialysis with low-flux dialyzer (LFD) also expressed different levels of CD63 compared with healthy controls. (b) The activation of basophils by anti-FcεRI was not significantly different between the groups. CD63 expression in activated basophils following dialysis with low-flux and high-flux dialyzers. Scatter plots represent the range with whiskers and the median as the middle line. A P value &lt;0.05 was considered significant. (a) The basophil activation response following stimulation with fMLP was significantly different when comparing samples obtained after dialysis with the low-flux dialyzer (LFD) to those after dialysis with the highflux dialyzer (HFD). (b) Anti-FcεRI antibodyactivated basophils expressed higher levels of CD63 after dialysis with the LFD membrane compared with before dialysis and also compared with those that underwent dialysis with the HFD.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>FIG. 5 . 6 .</head><label>56</label><figDesc>Total CD11b expression on the surface of neutrophils before (baseline) and after stimulation with IL-8. Scatter plots represent the range with whiskers and the median as the middle line. P &lt; 0.05 was considered significant. (a) Total CD11b expression on neutrophils before stimulation with IL-8. (b) Total CD11b expression on neutrophils after stimulation with IL-8. There were no significant differences between the groups. CD11b active epitope expression on the surface of neutrophils before (baseline) and after stimulation with IL-8. Scatter plots represent the range with whiskers and the median as the middle line. A P value &lt;0.05 was considered significant. (a) Active CD11b expression in neutrophils before stimulation with IL-8. (b) Active CD11b expression in neutrophils after stimulation with IL-8. There were no significant differences between the groups.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>TABLE 1 .</head><label>1</label><figDesc>Demographic characteristics of participants</figDesc><table><row><cell>Category</cell><cell>Healthy controls</cell><cell>Hemodialysis</cell></row><row><cell>Sex</cell><cell></cell><cell></cell></row><row><cell>Male (n)</cell><cell>5</cell><cell>5</cell></row><row><cell>Female (n)</cell><cell>5</cell><cell>5</cell></row><row><cell>Age (years), range (median)</cell><cell>33-81 (64.5)</cell><cell>37-76 (62.5)</cell></row><row><cell>Comorbidities (n)</cell><cell></cell><cell></cell></row><row><cell>Diabetes</cell><cell>0</cell><cell>2</cell></row><row><cell>History of heart disease</cell><cell>0</cell><cell>4</cell></row><row><cell>Hypertension</cell><cell>0</cell><cell>9</cell></row><row><cell>Family history of kidney disease (n)</cell><cell>0</cell><cell>3</cell></row><row><cell>Treatment (n)</cell><cell></cell><cell></cell></row><row><cell>ACE inhibitors/ARB</cell><cell>0</cell><cell>5</cell></row><row><cell>ESA</cell><cell>0</cell><cell>9</cell></row><row><cell>Intravenous iron</cell><cell>0</cell><cell>8</cell></row><row><cell>Vitamin D</cell><cell>0</cell><cell>9</cell></row><row><cell>Smoking (n)</cell><cell>0</cell><cell>0</cell></row><row><cell>Swedish snuff (n)</cell><cell>0</cell><cell>2</cell></row></table><note>ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers; ESA, erythropoiesis-stimulating agent.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>TABLE 3 .</head><label>3</label><figDesc>Absolute number of basophils (cell/μL) in peripheral whole blood</figDesc><table><row><cell></cell><cell>Pre-HFD</cell><cell>Post-HFD</cell><cell>Pre-LFD</cell><cell>Post-LFD</cell><cell>Healthy</cell></row><row><cell>Number of basophils/μL blood</cell><cell>16 (12-32)</cell><cell>23 (12-31)</cell><cell>25 (16-36)</cell><cell>28(17-51)</cell><cell>27 (15-39)</cell></row></table><note></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Artif Organs, Vol.38, No. 11, 2014   </note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0" />
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Sweden; Hesselman Foundation; and Amgen. We would like to thank Anette Bygdén-Nylander and Sofia Geschwind for excellent technical assistance.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict of Interest:</head><p>None.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Prevalence estimates of chronic kidney disease in Canada: results of a nationally representative survey</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Arora</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Vasa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Brenner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Iglar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Mcfarlane</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Morrison</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Badawi</surname></persName>
		</author>
		<idno type="DOI">10.1503/cmaj.120833</idno>
		<idno type="PMID">23649413</idno>
		<idno type="PMCID">PMC3680588</idno>
		<ptr type="open-access" target="http://www.cmaj.ca/content/cmaj/185/9/E417.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Canadian Medical Association Journal</title>
		<title level="j" type="abbrev">Canadian Medical Association Journal</title>
		<idno type="ISSN">0820-3946</idno>
		<idno type="ISSNe">1488-2329</idno>
		<imprint>
			<biblScope unit="volume">185</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="E417" to="E423" />
			<date type="published" when="2013-05-06" />
			<publisher>Joule Inc.</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third national health and nutrition examination survey</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Josef</forename><surname>Coresh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Brad</forename><forename type="middle">C</forename><surname>Astor</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tom</forename><surname>Greene</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Garabed</forename><surname>Eknoyan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andrew</forename><forename type="middle">S</forename><surname>Levey</surname></persName>
		</author>
		<idno type="DOI">10.1053/ajkd.2003.50007</idno>
		<idno type="PMID">12500213</idno>
	</analytic>
	<monogr>
		<title level="j">American Journal of Kidney Diseases</title>
		<title level="j" type="abbrev">American Journal of Kidney Diseases</title>
		<idno type="ISSN">0272-6386</idno>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="1" to="12" />
			<date type="published" when="2003-01" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Effect of Uremia on Structure and Function of Immune System</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nosratola</forename><forename type="middle">D</forename><surname>Vaziri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Madeleine</forename><forename type="middle">V</forename><surname>Pahl</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Albert</forename><surname>Crum</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Keith</forename><surname>Norris</surname></persName>
		</author>
		<idno type="DOI">10.1053/j.jrn.2011.10.020</idno>
		<idno type="PMID">22200433</idno>
		<idno type="PMCID">PMC3246616</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc3246616?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">Journal of Renal Nutrition</title>
		<title level="j" type="abbrev">Journal of Renal Nutrition</title>
		<idno type="ISSN">1051-2276</idno>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="149" to="156" />
			<date type="published" when="2012-01" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Mortality caused by sepsis in patients with end-stage renal disease compared with the general population</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mark</forename><forename type="middle">J</forename><surname>Sarnak</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">L</forename><surname>Jaber</surname></persName>
		</author>
		<idno type="DOI">10.1046/j.1523-1755.2000.00337.x</idno>
		<idno type="PMID">11012910</idno>
		<ptr type="open-access" target="http://www.kidney-international.org/article/S0085253815472746/pdf" />
	</analytic>
	<monogr>
		<title level="j">Kidney International</title>
		<title level="j" type="abbrev">Kidney Int</title>
		<idno type="ISSN">0085-2538</idno>
		<idno type="ISSNe">1523-1755</idno>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page">1758</biblScope>
			<date type="published" when="2000-10" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Effect of dialysis membrane biocompatibility on polymorphonuclear granulocyte activity in dialysis patients</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Banche</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Allizond</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Giacchino</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Mandras</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Roana</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Bonello</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Belardi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Tullio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Merlino</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Carlone</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">M</forename><surname>Cuffini</surname></persName>
		</author>
		<idno type="DOI">10.1093/ndt/gfl415</idno>
		<idno type="PMID">16935897</idno>
		<idno type="ark">ark:/67375/HXZ-448Z2VZJ-3</idno>
		<idno type="istexId">27285A65BE82C1DE7738CB7C4A77BC19CB3415A4</idno>
		<ptr type="open-access" target="https://academic.oup.com/ndt/article-pdf/21/12/3532/7986637/gfl415.pdf" />
	</analytic>
	<monogr>
		<title level="j">Nephrology Dialysis Transplantation</title>
		<title level="j" type="abbrev">Nephrology Dialysis Transplantation</title>
		<idno type="ISSN">0931-0509</idno>
		<idno type="ISSNe">1460-2385</idno>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="3532" to="3538" />
			<date type="published" when="2006-09-23" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Dialyzer membrane type and reuse practice influence polymorphonuclear leukocyte function in hemodialysis patients</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Madhumathi</forename><surname>Rao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Daqing</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bertrand</forename><forename type="middle">L</forename><surname>Jaber</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sumuk</forename><surname>Sundaram</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Miguel</forename><surname>Cendoroglo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andrew</forename><forename type="middle">J</forename><surname>King</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Brian</forename><forename type="middle">J G</forename><surname>Pereira</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Vaidyanathapuram</forename><forename type="middle">S</forename><surname>Balakrishnan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>The Hemo Study Group</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1523-1755.2004.00429.x</idno>
		<idno type="PMID">14717942</idno>
	</analytic>
	<monogr>
		<title level="j">Kidney International</title>
		<title level="j" type="abbrev">Kidney International</title>
		<idno type="ISSN">0085-2538</idno>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="682" to="691" />
			<date type="published" when="2004-02" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Influence of polysulfone and hemophan hemodialysis membranes on phagocytes</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Kubala</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Ciz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Soska</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Cerny</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Lojek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gen Physiol Biophys</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="367" to="80" />
			<date type="published" when="2002" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes.</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">R</forename><surname>Craddock</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Fehr</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">P</forename><surname>Dalmasso</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">L</forename><surname>Brighan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">S</forename><surname>Jacob</surname></persName>
		</author>
		<idno type="DOI">10.1172/jci108710</idno>
		<idno type="PMID">856872</idno>
		<idno type="PMCID">PMC372296</idno>
		<ptr type="open-access" target="http://www.jci.org/articles/view/108710/files/pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of Clinical Investigation</title>
		<title level="j" type="abbrev">J. Clin. Invest.</title>
		<idno type="ISSN">0021-9738</idno>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="879" to="888" />
			<date type="published" when="1977-05-01" />
			<publisher>American Society for Clinical Investigation</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Reduction of granulocyte activation during hemodialysis with regional citrate anticoagulation: dissociation of complement activation and neutropenia from neutrophil degranulation</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Bohler</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Schollmeyer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Dressel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Dobos</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">H</forename><surname>Horl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="234" to="275" />
			<date type="published" when="1996" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Activation of the complement system at the interface between blood and artificial surfaces</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">D</forename><surname>Kazatchkine</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">P</forename><surname>Carreno</surname></persName>
		</author>
		<idno type="DOI">10.1016/b978-008045154-1.50007-1</idno>
	</analytic>
	<monogr>
		<title level="m">The Biomaterials: Silver Jubilee Compendium</title>
		<imprint>
			<publisher>Elsevier</publisher>
			<date type="published" when="1988" />
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="45" to="50" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Complement Activation and Hypersensitivity Reactions to Dialysis Membranes</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Raymond</forename><forename type="middle">M</forename><surname>Hakim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Julian</forename><surname>Breillatt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">Michael</forename><surname>Lazarus</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Friedrich</forename><forename type="middle">K</forename><surname>Port</surname></persName>
		</author>
		<idno type="DOI">10.1056/nejm198410043111403</idno>
		<idno type="PMID">6332276</idno>
	</analytic>
	<monogr>
		<title level="j">New England Journal of Medicine</title>
		<title level="j" type="abbrev">N Engl J Med</title>
		<idno type="ISSN">0028-4793</idno>
		<idno type="ISSNe">1533-4406</idno>
		<imprint>
			<biblScope unit="volume">311</biblScope>
			<biblScope unit="issue">14</biblScope>
			<biblScope unit="page" from="878" to="882" />
			<date type="published" when="1984-10-04" />
			<publisher>New England Journal of Medicine (NEJM/MMS)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Dialyzer membrane permeability and survival in hemodialysis patients</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Philippe</forename><surname>Chauveau</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hiep</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Christian</forename><surname>Combe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Geneviève</forename><surname>Chêne</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Raymond</forename><surname>Azar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Noël</forename><surname>Cano</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bernard</forename><surname>Canaud</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Denis</forename><surname>Fouque</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Maurice</forename><surname>Laville</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xavier</forename><surname>Leverve</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hubert</forename><surname>Roth</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michel</forename><surname>Aparicio</surname></persName>
		</author>
		<idno type="DOI">10.1053/j.ajkd.2004.11.014</idno>
		<idno type="PMID">15754279</idno>
	</analytic>
	<monogr>
		<title level="j">American Journal of Kidney Diseases</title>
		<title level="j" type="abbrev">American Journal of Kidney Diseases</title>
		<idno type="ISSN">0272-6386</idno>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="565" to="571" />
			<date type="published" when="2005-03" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Effects of High-Flux Hemodialysis on Clinical Outcomes: Results of the HEMO Study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">K</forename><surname>Cheung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">W</forename><surname>Levin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Greene</surname></persName>
		</author>
		<idno type="DOI">10.1097/01.asn.0000096373.13406.94</idno>
		<idno type="PMID">14638924</idno>
		<ptr type="open-access" target="https://jasn.asnjournals.org/content/14/12/3251.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of the American Society of Nephrology</title>
		<title level="j" type="abbrev">Journal of the American Society of Nephrology</title>
		<idno type="ISSN">1046-6673</idno>
		<idno type="ISSNe">1533-3450</idno>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="3251" to="3263" />
			<date type="published" when="2003-12-01" />
			<publisher>American Society of Nephrology (ASN)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Effect of Membrane Permeability on Survival of Hemodialysis Patients</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Locatelli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Martin-Malo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Hannedouche</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Loureiro</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Papadimitriou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Wizemann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">H</forename><surname>Jacobson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Czekalski</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Ronco</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Vanholder</surname></persName>
		</author>
		<idno type="DOI">10.1681/asn.2008060590</idno>
		<idno type="PMID">19092122</idno>
		<idno type="PMCID">PMC2653681</idno>
		<ptr type="open-access" target="http://jasn.asnjournals.org/content/20/3/645.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of the American Society of Nephrology</title>
		<title level="j" type="abbrev">Journal of the American Society of Nephrology</title>
		<idno type="ISSN">1046-6673</idno>
		<idno type="ISSNe">1533-3450</idno>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="645" to="654" />
			<date type="published" when="2009-02-25" />
			<publisher>American Society of Nephrology (ASN)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Human basophils interact with memory T cells to augment Th17 responses</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Wakahara</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Baba</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><forename type="middle">Q</forename><surname>Van</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Begin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Rubio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Ferraro</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Panzini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Wassef</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Lahaie</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Caussignac</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Tamaz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Richard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Soucy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Delespesse</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Sarfati</surname></persName>
		</author>
		<idno type="DOI">10.1182/blood-2012-04-424226</idno>
		<idno type="PMID">23071273</idno>
		<ptr type="open-access" target="http://pdfs.semanticscholar.org/6fcf/2cc4b609406ceb886b26d416dbd1d6efc2ba.pdf" />
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<title level="j" type="abbrev">Blood</title>
		<idno type="ISSN">0006-4971</idno>
		<idno type="ISSNe">1528-0020</idno>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="issue">24</biblScope>
			<biblScope unit="page" from="4761" to="4771" />
			<date type="published" when="2012-10-15" />
			<publisher>American Society of Hematology</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Basophils and mast cells in renal injury</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Matthias</forename><surname>Mack</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alexander</forename><forename type="middle">R</forename><surname>Rosenkranz</surname></persName>
		</author>
		<idno type="DOI">10.1038/ki.2009.320</idno>
		<idno type="PMID">19692999</idno>
		<idno type="PMCID">PMC3227736</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc3227736?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">Kidney International</title>
		<title level="j" type="abbrev">Kidney International</title>
		<idno type="ISSN">0085-2538</idno>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1142" to="1147" />
			<date type="published" when="2009-12" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Basophils, IgE, and Autoantibody-Mediated Kidney Disease</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><surname>Bosch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Lozano</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Cervera</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Ramos-Casals</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Min</surname></persName>
		</author>
		<idno type="DOI">10.4049/jimmunol.1002648</idno>
		<idno type="PMID">21597041</idno>
		<idno type="PMCID">PMC3466044</idno>
		<ptr type="open-access" target="http://www.jimmunol.org/content/jimmunol/186/11/6083.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">The Journal of Immunology</title>
		<title level="j" type="abbrev">The Journal of Immunology</title>
		<idno type="ISSN">0022-1767</idno>
		<idno type="ISSNe">1550-6606</idno>
		<imprint>
			<biblScope unit="volume">186</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="6083" to="6090" />
			<date type="published" when="2011-05-19" />
			<publisher>The American Association of Immunologists</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Haemodialysis-associated anaphylactic and anaphylactoid reactions</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">G</forename><surname>Ebo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">L</forename><surname>Bosmans</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">M</forename><surname>Couttenye</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><forename type="middle">J</forename><surname>Stevens</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1398-9995.2006.00982.x</idno>
		<idno type="PMID">16409199</idno>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<title level="j" type="abbrev">Allergy</title>
		<idno type="ISSN">0105-4538</idno>
		<idno type="ISSNe">1398-9995</idno>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="211" to="220" />
			<date type="published" when="2006-02" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Anaphylactic shock caused by formaldehyde in a patient undergoing long-term hemodialysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Maurice</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">P</forename><surname>Rivory</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">H</forename><surname>Larsson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">G</forename><surname>Johansson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Bousquet</surname></persName>
		</author>
		<idno type="DOI">10.1016/0091-6749(86)90351-9</idno>
		<idno type="PMID">3958388</idno>
		<idno type="PII">0091-6749(86)90351-9</idno>
		<idno type="ark">ark:/67375/6H6-LRL0DBB1-3</idno>
		<idno type="istexId">F2DD8B0FF1AA31F5216B4DF8B3FDA6FAA3E7CABB</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Allergy and Clinical Immunology</title>
		<title level="j" type="abbrev">Journal of Allergy and Clinical Immunology</title>
		<idno type="ISSN">0091-6749</idno>
		<imprint>
			<biblScope unit="volume">77</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="594" to="597" />
			<date type="published" when="1986-04" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Ultrapure dialysis fluid--how pure is it and do we need it?</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Ledebo</surname></persName>
		</author>
		<idno type="DOI">10.1093/ndt/gfl574</idno>
		<idno type="PMID">17035373</idno>
		<idno type="ark">ark:/67375/HXZ-W8T2J5MK-K</idno>
		<idno type="istexId">4951A947DA570F0AF8305F5650F9B9A5ED9534D1</idno>
		<ptr type="open-access" target="https://academic.oup.com/ndt/article-pdf/22/1/20/7991769/gfl574.pdf" />
	</analytic>
	<monogr>
		<title level="j">Nephrology Dialysis Transplantation</title>
		<title level="j" type="abbrev">Nephrology Dialysis Transplantation</title>
		<idno type="ISSN">0931-0509</idno>
		<idno type="ISSNe">1460-2385</idno>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="20" to="23" />
			<date type="published" when="2006-10-18" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Passive IgE-sensitization by blood transfusion</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">G O</forename><surname>Johansson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Nopp</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Hage</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Olofsson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Lundahl</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Wehlin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Soderstrom</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Stiller</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Oman</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1398-9995.2005.00870.x</idno>
		<idno type="PMID">16076307</idno>
	</analytic>
	<monogr>
		<title level="j">Allergy</title>
		<title level="j" type="abbrev">Allergy</title>
		<idno type="ISSN">0105-4538</idno>
		<idno type="ISSNe">1398-9995</idno>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="1192" to="1199" />
			<date type="published" when="2005-09" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">IL-8 from Local Subcutaneous Wounds Regulates CD11b Activation</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Lundahl</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">H</forename><surname>Jacobson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Paulsson</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1365-3083.2012.02679.x</idno>
		<idno type="PMID">22229891</idno>
		<idno type="ark">ark:/67375/WNG-2FWNQD5Q-Q</idno>
		<idno type="istexId">8F4325A79B93FA246EE1D5B6A13C78864510E912</idno>
	</analytic>
	<monogr>
		<title level="j">Scandinavian Journal of Immunology</title>
		<idno type="ISSN">0300-9475</idno>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="419" to="425" />
			<date type="published" when="2012-03-16" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Phosphatidylinositol-3 kinase regulates p21ras activation during IgE-mediated stimulation of human basophils</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Maura</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Macglashan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="2199" to="205" />
			<date type="published" when="2000" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Urokinase Induces Basophil Chemotaxis through a Urokinase Receptor Epitope That Is an Endogenous Ligand for Formyl Peptide Receptor-Like 1 and -Like 2</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>De Paulis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Montuori</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Prevete</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Fiorentino</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><forename type="middle">W</forename><surname>Rossi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Visconte</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Rossi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Marone</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Ragno</surname></persName>
		</author>
		<idno type="DOI">10.4049/jimmunol.173.9.5739</idno>
		<idno type="PMID">15494526</idno>
		<ptr type="open-access" target="http://www.jimmunol.org/content/173/9/5739.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">The Journal of Immunology</title>
		<title level="j" type="abbrev">The Journal of Immunology</title>
		<idno type="ISSN">0022-1767</idno>
		<idno type="ISSNe">1550-6606</idno>
		<imprint>
			<biblScope unit="volume">173</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="5739" to="5748" />
			<date type="published" when="2004-10-19" />
			<publisher>The American Association of Immunologists</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Basophil Activation Antigens: Molecular Mechanisms and Clinical Implications</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Peter</forename><surname>Valent</surname></persName>
		</author>
		<idno type="DOI">10.2174/1874838401003010052</idno>
		<ptr type="open-access" target="http://benthamopen.com/contents/pdf/TOALLJ/TOALLJ-3-52.pdf" />
	</analytic>
	<monogr>
		<title level="j">The Open Allergy Journal</title>
		<title level="j" type="abbrev">TOALLJ</title>
		<idno type="ISSN">1874-8384</idno>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="52" to="59" />
			<date type="published" when="2010-11-26" />
			<publisher>Bentham Science Publishers Ltd.</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Use of both CD63 up regulation and IgE down regulation for the flow cytometric analysis of allergen induced basophil activation</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Laudy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Boumediene</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Tourane</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Inflamm Res</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="291" to="297" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Garabed</forename><surname>Eknoyan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gerald</forename><forename type="middle">J</forename><surname>Beck</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alfred</forename><forename type="middle">K</forename><surname>Cheung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">John</forename><forename type="middle">T</forename><surname>Daugirdas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tom</forename><surname>Greene</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">John</forename><forename type="middle">W</forename><surname>Kusek</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><surname>Allon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">James</forename><surname>Bailey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">James</forename><forename type="middle">A</forename><surname>Delmez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Thomas</forename><forename type="middle">A</forename><surname>Depner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Johanna</forename><forename type="middle">T</forename><surname>Dwyer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andrew</forename><forename type="middle">S</forename><surname>Levey</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nathan</forename><forename type="middle">W</forename><surname>Levin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Edgar</forename><surname>Milford</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Daniel</forename><forename type="middle">B</forename><surname>Ornt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><forename type="middle">V</forename><surname>Rocco</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gerald</forename><surname>Schulman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Steve</forename><forename type="middle">J</forename><surname>Schwab</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Brendan</forename><forename type="middle">P</forename><surname>Teehan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Robert</forename><surname>Toto</surname></persName>
		</author>
		<idno type="DOI">10.1056/nejmoa021583</idno>
		<idno type="PMID">12490682</idno>
	</analytic>
	<monogr>
		<title level="j">New England Journal of Medicine</title>
		<title level="j" type="abbrev">N Engl J Med</title>
		<idno type="ISSN">0028-4793</idno>
		<idno type="ISSNe">1533-4406</idno>
		<imprint>
			<biblScope unit="volume">347</biblScope>
			<biblScope unit="issue">25</biblScope>
			<biblScope unit="page" from="2010" to="2019" />
			<date type="published" when="2002-12-19" />
			<publisher>New England Journal of Medicine (NEJM/MMS)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Effect of hemodialysis with cuprophane and polysulfone membranes on counts of leukocytes, granulocytes, monocytes, lymphocytes and lymphocyte subsets</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Moczulski</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Zukowska-Szczechowska</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Grzezsczak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pol Arch Med Wewn</title>
		<imprint>
			<biblScope unit="volume">92</biblScope>
			<biblScope unit="page">426</biblScope>
			<date type="published" when="1994" />
		</imprint>
	</monogr>
	<note>Polish</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Hemodialysis effect on platelet count and function and hemodialysis-associated thrombocytopenia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">John</forename><forename type="middle">T</forename><surname>Daugirdas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Angelito</forename><forename type="middle">A</forename><surname>Bernardo</surname></persName>
		</author>
		<idno type="DOI">10.1038/ki.2012.130</idno>
		<idno type="PMID">22592187</idno>
		<ptr type="open-access" target="http://www.kidney-international.org/article/S0085253815555154/pdf" />
	</analytic>
	<monogr>
		<title level="j">Kidney International</title>
		<title level="j" type="abbrev">Kidney International</title>
		<idno type="ISSN">0085-2538</idno>
		<imprint>
			<biblScope unit="volume">82</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="147" to="157" />
			<date type="published" when="2012-07" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">The effect of hemodialysis and C5a des arg on neutrophil subpopulations</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Klempner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Gallin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Balow</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Van Kammen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="777" to="83" />
			<date type="published" when="1980" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Structure and function of the leukocyte adhesion molecules CD11/CD18</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">A</forename><surname>Arnaout</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="1037" to="50" />
			<date type="published" when="1990" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Dissociation between complement activation, integrin expression and neutropenia during hemodialysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Rousseau</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M-P</forename><surname>Carreno</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J-L</forename><surname>Poignet</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">D</forename><surname>Kazatchkine</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Haeffner-Cavaillon</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0142-9612(99)00101-5</idno>
		<idno type="PMID">10514074</idno>
		<idno type="PII">S0142-9612(99)00101-5</idno>
		<idno type="ark">ark:/67375/6H6-KG1HQRBR-P</idno>
		<idno type="istexId">753E7BE8A9B21E0AEEF95816943974D69745288B</idno>
	</analytic>
	<monogr>
		<title level="j">Biomaterials</title>
		<title level="j" type="abbrev">Biomaterials</title>
		<idno type="ISSN">0142-9612</idno>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">20</biblScope>
			<biblScope unit="page" from="1959" to="1967" />
			<date type="published" when="1999-10" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Surface Antigen Expression and Platelet Neutrophil Interactions in Haemodialysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Bonomini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Sirolli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Settefrati</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Stuard</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Tropea</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Di Liberato</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Tetta</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Albertazzi</surname></persName>
		</author>
		<idno type="DOI">10.1159/000014382</idno>
		<idno type="PMID">10449868</idno>
	</analytic>
	<monogr>
		<title level="j">Blood Purification</title>
		<title level="j" type="abbrev">Blood Purif</title>
		<idno type="ISSN">0253-5068</idno>
		<idno type="ISSNe">1421-9735</idno>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="issue">2-3</biblScope>
			<biblScope unit="page" from="107" to="117" />
			<date type="published" when="1999" />
			<publisher>S. Karger AG</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Score Model for the Evaluation of Dialysis Membrane Hemocompatibility</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ansgar</forename><surname>Erlenkötter</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Pia</forename><surname>Endres</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bernd</forename><surname>Nederlof</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Carsten</forename><surname>Hornig</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jörg</forename><surname>Vienken</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1525-1594.2008.00657.x</idno>
		<idno type="PMID">19133025</idno>
		<idno type="ark">ark:/67375/WNG-JV94MM24-4</idno>
		<idno type="istexId">67EF57AA49370D5466EDCE63296E5CC27DAF4CEA</idno>
	</analytic>
	<monogr>
		<title level="j">Artificial Organs</title>
		<idno type="ISSN">0160-564X</idno>
		<idno type="ISSNe">1525-1594</idno>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="962" to="969" />
			<date type="published" when="2008-12" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Effect of permeability on indices of haemodialysis membrane biocompatibility</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Masaki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Gilson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">K</forename><surname>Leypoldt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">K</forename><surname>Cheung</surname></persName>
		</author>
		<idno type="DOI">10.1093/ndt/14.5.1176</idno>
		<idno type="PMID">10344358</idno>
		<ptr type="open-access" target="https://academic.oup.com/ndt/article-pdf/14/5/1176/9898699/141176.pdf" />
	</analytic>
	<monogr>
		<title level="j">Nephrology Dialysis Transplantation</title>
		<idno type="ISSNe">1460-2385</idno>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1176" to="1181" />
			<date type="published" when="1999-05-01" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Redistribution of P-selectin ligands on neutrophil cell membranes and the formation of platelet–neutrophil complex induced by hemodialysis membranes</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Saotomo</forename><surname>Itoh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kana</forename><surname>Takeshita</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chie</forename><surname>Susuki</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kazunori</forename><surname>Shige-Eda</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tsutomu</forename><surname>Tsuji</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.biomaterials.2008.04.018</idno>
		<idno type="PMID">18452987</idno>
	</analytic>
	<monogr>
		<title level="j">Biomaterials</title>
		<title level="j" type="abbrev">Biomaterials</title>
		<idno type="ISSN">0142-9612</idno>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">21</biblScope>
			<biblScope unit="page" from="3084" to="3090" />
			<date type="published" when="2008-07" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ioannis</forename><surname>Kourtzelis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Maciej</forename><forename type="middle">M</forename><surname>Markiewski</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><surname>Doumas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stavros</forename><surname>Rafail</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Konstantinos</forename><surname>Kambas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ioannis</forename><surname>Mitroulis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stelios</forename><surname>Panagoutsos</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ploumis</forename><surname>Passadakis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Vasilios</forename><surname>Vargemezis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paola</forename><surname>Magotti</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.molimm.2010.05.255</idno>
	</analytic>
	<monogr>
		<title level="j">Molecular Immunology</title>
		<title level="j" type="abbrev">Molecular Immunology</title>
		<idno type="ISSN">0161-5890</idno>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="issue">13</biblScope>
			<biblScope unit="page" from="2284" to="2284" />
			<date type="published" when="2010-08" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Interleukin 1 releases histamine from human basophils and mast cells in vitro</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Subramanian</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Bray</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Immunol</title>
		<imprint>
			<biblScope unit="volume">138</biblScope>
			<biblScope unit="page" from="271" to="276" />
			<date type="published" when="1987" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Bradykinin is a mediator of anaphylactoid reactions during hemodialysis with AN69 membranes</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Luc</forename><surname>Verresen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Edwin</forename><surname>Fink</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Horst-Dieter</forename><surname>Lemke</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yves</forename><surname>Vanrenterghem</surname></persName>
		</author>
		<idno type="DOI">10.1038/ki.1994.195</idno>
		<idno type="PMID">8072263</idno>
		<ptr type="open-access" target="https://epub.ub.uni-muenchen.de/9769/1/Fink_Edwin_9769.pdf" />
	</analytic>
	<monogr>
		<title level="j">Kidney International</title>
		<title level="j" type="abbrev">Kidney International</title>
		<idno type="ISSN">0085-2538</idno>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1497" to="1503" />
			<date type="published" when="1994-05" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Clinical implications of hemodialysis membrane biocompatibility</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">M</forename><surname>Raymond</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Nashville</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Kidney Int</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="484" to="94" />
			<date type="published" when="1993" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Leukocyte Proliferation and Immune Modulator Production in Patients with Chronic Kidney Disease</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ladan</forename><surname>Mansouri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Josefin</forename><forename type="middle">M</forename><surname>Paulsson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ali</forename><surname>Moshfegh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stefan</forename><forename type="middle">H</forename><surname>Jacobson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Joachim</forename><surname>Lundahl</surname></persName>
		</author>
		<idno type="DOI">10.1371/journal.pone.0073141</idno>
		<idno type="PMID">23951343</idno>
		<idno type="PMCID">PMC3739766</idno>
		<ptr type="open-access" target="https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0073141&amp;type=printable" />
	</analytic>
	<monogr>
		<title level="j">PLoS ONE</title>
		<title level="j" type="abbrev">PLoS ONE</title>
		<idno type="ISSNe">1932-6203</idno>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page">e73141</biblScope>
			<date type="published" when="2013-08-09" />
			<publisher>Public Library of Science (PLoS)</publisher>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
